Juan Macías-rekin lankidetzan egindako argitalpenak (10)

2024

  1. Long or complicated mpox in patients with uncontrolled HIV infection

    Journal of Medical Virology, Vol. 96, Núm. 3

2017

  1. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study

    PLoS ONE, Vol. 11, Núm. 5

2013

  1. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  2. Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV

    PLoS ONE, Vol. 8, Núm. 7

2011

  1. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 11, pp. 2605-2614

  2. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 6, pp. 1351-1353

2010

  1. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 10, pp. 2204-2211

  2. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: Role of didanosine

    Antiviral Therapy, Vol. 15, Núm. 5, pp. 753-763

2009

  1. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients

    Gut, Vol. 58, Núm. 12, pp. 1654-1660